Acumen Cash And Short Term Investments from 2010 to 2024
| ABOS Stock | USD 2.27 0.01 0.44% |
Cash And Short Term Investments | First Reported 2010-12-31 | Previous Quarter 243.5 M | Current Value 146.5 M | Quarterly Volatility 85.3 M |
Check Acumen Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acumen Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 8.6 M, Interest Income of 8.6 M or Depreciation And Amortization of 174.8 K, as well as many indicators such as Price To Sales Ratio of 415, Dividend Yield of 0.0 or PTB Ratio of 0.73. Acumen financial statements analysis is a perfect complement when working with Acumen Pharmaceuticals Valuation or Volatility modules.
Acumen | Cash And Short Term Investments |
Latest Acumen Pharmaceuticals' Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of Acumen Pharmaceuticals over the last few years. Short Term Investments is an account in the current assets section of Acumen Pharmaceuticals balance sheet. This account contains Acumen Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Acumen Pharmaceuticals fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Acumen Pharmaceuticals' Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acumen Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
Acumen Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 58,074,231 | |
| Geometric Mean | 18,183,067 | |
| Coefficient Of Variation | 146.82 | |
| Mean Deviation | 70,602,605 | |
| Median | 6,552,000 | |
| Standard Deviation | 85,264,004 | |
| Sample Variance | 7270T | |
| Range | 237M | |
| R-Value | 0.77 | |
| Mean Square Error | 3168.6T | |
| R-Squared | 0.60 | |
| Significance | 0.0008 | |
| Slope | 14,710,012 | |
| Total Sum of Squares | 101779.3T |
Acumen Cash And Short Term Investments History
About Acumen Pharmaceuticals Financial Statements
Acumen Pharmaceuticals shareholders use historical fundamental indicators, such as Cash And Short Term Investments, to determine how well the company is positioned to perform in the future. Although Acumen Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Acumen Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Acumen Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 243.5 M | 146.5 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.